Across TCGA pan-cancer cohorts, FICD mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FICD data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher FICD mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FICD expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

UCEC, LUAD, and GBM are the cancer types where FICD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Quartile	All	1.000	0.147	.036	8	view →
LUAD	OS	Median	III,IV	0.312	0.753	.031	3	view →
GBM	OS	Median	All	0.894	0.744	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: FICD tumor-vs-normal RNA expression · all FICD data types